/Gilead%20Sciences%2C%20Inc_%20Meeting%20Center-by%20Sundry%20Photography%20via%20iStock.jpg)
Gilead Sciences, Inc. (GILD), based in Foster City, California, is a leading biopharmaceutical company focused on developing and commercializing groundbreaking therapies for diseases like HIV, liver conditions, cancer, and inflammation. Its market cap currently stands at $129 billion.
Gilead is poised to release its fiscal Q1 earnings results after the market closes on Thursday, Apr. 24. Ahead of the event, analysts expect GILD to report a profit of $1.73 per share, up 231.1% from the loss of $1.32 per share in the year-ago quarter. The company surpassed Wall Street’s bottom-line estimates in each of the past four quarters, which is impressive.